These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34210551)

  • 21. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.
    Tsui JI; Barry MP; Austin EJ; Sweek EW; Tung E; Hansen RN; Ninburg M; Scott JD; Glick SN; Williams EC
    Addict Sci Clin Pract; 2021 Aug; 16(1):52. PubMed ID: 34384494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multi-site, nurse-coordinated hepatitis C model of care in primary care and community services in Melbourne, Australia.
    Harney BL; Whitton B; Paige E; Brereton R; Weiss R; Membrey D; Wade AJ; Iser D; Kemp W; Roberts SK; Spelman T; Sacks-Davis R; Hellard ME; Doyle JS
    Liver Int; 2022 Mar; 42(3):522-531. PubMed ID: 34821021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reinfection following successful direct-acting antiviral therapy for HCV infection among people attending an inner-city community health centre in Victoria, Canada.
    Selfridge M; Cunningham EB; Barnett T; Drost A; Gray-Schleihauf C; Guarasci K; Lundgren K; Milne R; Grebely J; Fraser C
    Int J Drug Policy; 2021 Oct; 96():103418. PubMed ID: 34538704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis.
    Graf C; Mücke MM; Dultz G; Peiffer KH; Kubesch A; Ingiliz P; Zeuzem S; Herrmann E; Vermehren J
    Clin Infect Dis; 2020 May; 70(11):2355-2365. PubMed ID: 31513710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Innovative Approaches to Engaging Homeless and Marginally Housed Patients in Care: a Case Study of Hepatitis C.
    Conti J; Dryden E; Fincke BG; Dunlap S; McInnes DK
    J Gen Intern Med; 2023 Jan; 38(1):156-164. PubMed ID: 35879538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis.
    Simmons B; Saleem J; Hill A; Riley RD; Cooke GS
    Clin Infect Dis; 2016 Mar; 62(6):683-694. PubMed ID: 26787172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Hartwell D; Jones J; Baxter L; Shepherd J
    Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A hepatitis C elimination model in healthcare for the homeless organization: A novel reflexive laboratory algorithm and equity assessment.
    Seaman A; King CA; Kaser T; Geduldig A; Ronan W; Cook R; Chan B; Levander XA; Priest KC; Korthuis PT
    Int J Drug Policy; 2021 Oct; 96():103359. PubMed ID: 34325969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clients' perceptions of barriers and facilitators to implementing hepatitis C virus care in homeless shelters.
    Masson CL; Fokuo JK; Anderson A; Powell J; Zevin B; Bush D; Khalili M
    BMC Infect Dis; 2020 May; 20(1):386. PubMed ID: 32471376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study.
    Janjua NZ; Wong S; Abdia Y; Jeong D; Buller-Taylor T; Adu PA; Samji H; Wilton J; Pearce M; Butt ZA; Yu A; Binka M; Bartlett S; Alvarez M; Krajden M
    J Hepatol; 2021 Nov; 75(5):1049-1057. PubMed ID: 34097994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study.
    Alavi M; Poustchi H; Merat S; Kaveh-Ei S; Rahimi-Movaghar A; Shadloo B; Hajarizadeh B; Grebely J; Dore GJ; Malekzadeh R
    Int J Drug Policy; 2019 Oct; 72():99-105. PubMed ID: 31303262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of hepatitis C virus infection among key populations in China: A systematic review.
    Liu CR; Li X; Chan PL; Zhuang H; Jia JD; Wang X; Lo YR; Walsh N
    Int J Infect Dis; 2019 Mar; 80():16-27. PubMed ID: 30529371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 'HepCheck Dublin': an intensified hepatitis C screening programme in a homeless population demonstrates the need for alternative models of care.
    Lambert JS; Murtagh R; Menezes D; O'Carroll A; Murphy C; Cullen W; McHugh T; Avramovic G; Tinago W; Van Hout MC
    BMC Infect Dis; 2019 Feb; 19(1):128. PubMed ID: 30732573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation.
    Hartwell D; Cooper K; Frampton GK; Baxter L; Loveman E
    Health Technol Assess; 2014 Oct; 18(65):i-xxii, 1-202. PubMed ID: 25350588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.
    Platt L; Minozzi S; Reed J; Vickerman P; Hagan H; French C; Jordan A; Degenhardt L; Hope V; Hutchinson S; Maher L; Palmateer N; Taylor A; Bruneau J; Hickman M
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012021. PubMed ID: 28922449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of a Decentralized Hub and Spoke Model for the Treatment of Hepatitis C Virus in a Federally Qualified Health Center.
    Rojas SA; Godino JG; Northrup A; Khasira M; Tam A; Asmus L; Frenette C; Ramers CB
    Hepatol Commun; 2021 Mar; 5(3):412-423. PubMed ID: 33681676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elastography is unable to exclude cirrhosis after sustained virological response in HCV-infected patients with advanced chronic liver disease.
    Broquetas T; Herruzo-Pino P; Mariño Z; Naranjo D; Vergara M; Morillas RM; Forns X; Carrión JA
    Liver Int; 2021 Nov; 41(11):2733-2746. PubMed ID: 34525253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis.
    Hajarizadeh B; Cunningham EB; Reid H; Law M; Dore GJ; Grebely J
    Lancet Gastroenterol Hepatol; 2018 Nov; 3(11):754-767. PubMed ID: 30245064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.
    Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Amin J; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Midgard H; Bourgeois S; Staehelin C; Dore GJ;
    Int J Drug Policy; 2017 Sep; 47():177-186. PubMed ID: 28624134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.